关于参与设立产业投资基金的进展公告 证券代码：603309 证券简称：维力医疗 公告编号：2025-042 广州维力医疗器械股份有限公司 6、执行事务合伙人：橡栎医林投资（苏州）合伙企业（有限合伙） 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、对外投资基本情况 为了借助专业投资机构的产业资源和产业投资管理优势，落实公司战略发展 规划，广州维力医疗器械股份有限公司（以下简称"公司"）与橡栎医林投资（苏 州）合伙企业（有限合伙）、苏州天使投资引导基金（有限合伙）、橡栎莲芰(广 州)创业投资基金合伙企业 (有限合伙)于 2025 年 6 月 23 日签署了《维智医航（苏 州）医疗产业投资合伙企业（有限合伙）合伙协议》，公司拟作为有限合伙人参 与设立维智医航（苏州）医疗产业投资合伙企业（有限合伙）（以下简称"维智 医航"），维智医航拟募资规模为人民币 15,000 万元，公司拟认缴出资人民币 3,750 万元，占总认缴出资规模的 25%，资金来源为自有资金。（具体内容详见 公司 2025 年 6 月 24 日披露于《中国证券报 ...

Summary of Key Points Core Viewpoint The company, Guangzhou Weili Medical Instrument Co., Ltd., is participating in the establishment of an industrial investment fund named Weizhi Yihang (Suzhou) Medical Industry Investment Partnership (Limited Partnership) with a total investment of 37.5 million RMB, which represents 25% of the fund's total subscription amount of 150 million RMB. This investment aims to leverage professional investment management to align with the company's strategic development without affecting its main business operations [2][3][44]. Group 1: Investment Overview - The company has signed a partnership agreement to establish the Weizhi Yihang investment fund, with a total fundraising target of 150 million RMB [3][10]. - The company will contribute 37.5 million RMB from its own funds, which will not impact its normal business operations [3][44]. - The fund aims to invest in non-listed companies in the medical device and related sectors, focusing on those with good growth potential and core competitiveness [10][17]. Group 2: Partners and Fund Structure - The general partner of the fund is Xianglv Yilin Investment (Suzhou) Partnership (Limited Partnership), established on August 29, 2024, with a registered capital of 5 million RMB [5]. - Other limited partners include Suzhou Angel Investment Guidance Fund (Limited Partnership) and Xianglv Lianqi (Guangzhou) Venture Capital Fund Partnership (Limited Partnership), with registered capitals of 601 million RMB and 64.1 million RMB, respectively [8][9]. - The fund will have a lifespan of 10 years from the date of its first business license issuance [13]. Group 3: Investment Strategy and Management - The fund will focus on direct or indirect equity investments in non-listed enterprises within the medical industry, with a minimum of 15 projects targeted for investment [17]. - The fund's management will be handled by Xianglv Venture Capital Management (Guangzhou) Co., Ltd., which will oversee fundraising, investment decisions, and compliance with regulatory requirements [15][16]. - The fund will operate on a closed-end basis, with specific investment exit strategies outlined, including secondary market sales and direct equity transfers [21][22]. Group 4: Financial Implications and Risk Management - The investment is expected to enhance the company's strategic positioning without introducing new related transactions or competitive conflicts [44]. - The company will closely monitor the fund's operations and ensure compliance with legal and regulatory requirements [44]. - The establishment of the fund is subject to uncertainties, including the need for registration and potential challenges in fundraising [2][44].

Group 1 - Beixin Road and Bridge's application for issuing shares to specific targets has been approved by the Shenzhen Stock Exchange, pending approval from the China Securities Regulatory Commission [1] - Wangbian Electric's shareholders plan to reduce their holdings by a total of up to 2.99% of the company's shares, with specific reductions detailed for each shareholder [1] - Guotou Zhonglu is planning a major asset restructuring, leading to a suspension of its stock trading for up to 10 trading days [2] Group 2 - Baiotai has signed a licensing agreement with SteinCares for the commercialization of BAT2406 in Brazil and Latin America, with total payments potentially reaching up to $10 million [3] - Dongfang Bio has obtained two medical device registration certificates for its products, which are valid until June 1, 2030 [4] - Pulaike's subsidiary has received a new veterinary drug registration certificate [5] Group 3 - Wanyi Technology has signed an agreement to establish a joint laboratory with the Energy Research Institute, with a total research and development budget of 6 million yuan [6] - Yingboer plans to use up to 300 million yuan of idle funds for financial management [7] - Blue Biological has received two new veterinary drug registration certificates [8] Group 4 - Jinkai New Energy intends to inject up to 1.247 billion yuan into its wholly-owned subsidiary to enhance its operational capabilities [9] - China Pacific Insurance's assistant general manager's qualification has been approved [10] - Zhaoyan New Drug is reducing its registered capital and notifying creditors [11] Group 5 - Weili Medical plans to invest 37.5 million yuan in establishing a medical industry investment fund [12] - Hongbai New Materials has signed a deposit agreement for idle raised funds [13] - Tongyou Technology is applying for a credit limit of 10 million yuan from a bank [14] Group 6 - Warner Pharmaceutical's subsidiary has received approval for its magnesium sulfate raw material drug [15] - Fuda Co. plans to establish a wholly-owned subsidiary with a capital contribution of 475 million yuan [16] - Yabao Pharmaceutical has obtained a loan commitment letter for stock repurchase of up to 90 million yuan [17] Group 7 - Zhongyin Securities' chairman has resigned due to work adjustments [18] - Aili Home has terminated its share reduction plan ahead of schedule [19] - Samsung New Materials has appointed a new financial officer [20] Group 8 - Guobang Pharmaceutical's subsidiary has received EU GMP certification for its product [21] - Yipin Hong has received a drug registration certificate for its injection solution [22] - Wenzhou Hongfeng's subsidiary has obtained a utility model patent certificate [23] Group 9 - Cangge Mining plans to sign a financial service agreement with Zijin Mining Group [24] - Naipu Mining's application for convertible bonds has been accepted by the Shenzhen Stock Exchange [25] - Shenyang Machine Tool has completed its major asset restructuring [26] Group 10 - Xinlaifu plans to distribute a cash dividend of 5 yuan per 10 shares [27] - Jiashitang plans to distribute a cash dividend of 1.7 yuan per 10 shares [28] - Manbuer plans to distribute a cash dividend of 2.5 yuan per 10 shares [29] Group 11 - Guo Wang Yingda plans to distribute a cash dividend of 0.51 yuan per 10 shares [30] - Changsha Bank's shareholder plans to reduce holdings by up to 0.92% [31] - Hu Nong Commercial Bank plans to distribute a cash dividend of 1.93 yuan per 10 shares [32] Group 12 - Huaxiang Co. plans to distribute a cash dividend of 1.17 yuan per 10 shares [33]

证券代码：603309 证券简称：维力医疗 公告编号：2025-041 广州维力医疗器械股份有限公司 关于参与设立产业投资基金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资标的名称：维智医航（苏州）医疗产业投资合伙企业（有限合伙） （暂定名，以企业注册登记机关最终核准登记的名称为准） 投资金额：3,750 万元人民币 特别风险提示： 1、产业投资基金尚未成立，尚需进行工商注册登记并履行中国证券投资基 金业协会的备案程序，具体实施情况和进度存在一定的不确定性。 2、基金设立过程中可能存在因合伙人未能缴足认缴资金等客观原因，导致 未能募集到足够资金的风险。 3、投资基金具有投资期限长、流动性较低等特点，所投资项目可能受经济 环境、行业周期、监管政策及市场变化等多重不确定因素影响，可能存在项目退 出、投资收益不及预期的风险。 一、对外投资概述 为了借助专业投资机构的产业资源和产业投资管理优势，落实公司战略发展 规划，广州维力医疗器械股份有限公司（以下简称"维力医疗""公司"）与橡 栎医林投资（苏州）合伙 ...

维力医疗：拟认出资3750万元参与设立产业投资基金 金十数据6月23日讯，维力医疗与橡栎医林投资合伙企业、苏州天使投资引导基金、橡栎莲芰创业投资 基金合伙企业于近日签署了《维智医航医疗产业投资合伙企业合伙协议》，公司拟作为有限合伙人参与 设立维智医航医疗产业投资合伙企业，维智医航拟募资规模为人民币15,000万元，公司拟认缴出资人民 币3,750万元，占总认缴出资规模的25%，资金来源为自有资金。 ...

Group 1 - The core viewpoint of the article highlights that Yongxi Investment has conducted research on a listed company, Weili Medical, focusing on its strategies to expand overseas production in response to domestic medical consumables procurement and geopolitical risks [1] - Weili Medical is actively building a factory in Mexico starting in 2024, having completed land acquisition and project planning, while also preparing a second overseas production base in Indonesia to mitigate high tariffs imposed by the U.S. [1] - The company expects that by 2024, overseas business will account for approximately 54% of its total revenue, with North America contributing 34%, Europe 27%, Asia 15%, and South America 8% [1] Group 2 - Weili Medical has seen a significant increase in the gross profit margin of its overseas business, rising from 27% in 2021 to 35% in 2024, an increase of 8 percentage points [1] - The company is diversifying its export products, with a growing proportion of high-margin products being exported, which contributes to the overall improvement in gross profit margins [1]

证券代码：603309 证券简称：维力医疗 公告编号：2025-040 广州维力医疗器械股份有限公司 持证方：广州维力医疗器械股份有限公司 广州维力医疗器械股份有限公司（以下简称"公司"）于近日收到加拿大卫生 部颁发的 2 类医疗器械产品注册证，公司产品尿道扩张器套件（Urethral Dilator） 获得了加拿大卫生部认证。现将有关情况公告如下： 一、医疗器械注册证的具体情况 产品名称：尿道扩张器套件（Urethral Dilator） 证书编号：113487 型号/规格：Hydrophilic coating Dilator/Set/8-24Fr；Hydrophilic coating S Shape Dilator/Set/8-20Fr,14-26Fr,16-26Fr 关于公司产品获得加拿大卫生部认证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 持证方住所：广东省广州市番禺区化龙镇金湖工业城 C 区 4 号 公司上述产品在相应市场的实际销售情况取决于未来市场的推广效果，且受海 外市场政策环境等因素影响，目前尚 ...

Company Overview - Guangzhou Weili Medical Instrument Co., Ltd. specializes in the research, production, and sales of medical devices in fields such as anesthesia, catheterization, urology, nursing, respiration, and blood dialysis, widely used in open surgeries, minimally invasive surgeries, emergency care, and nursing [2] - The main products include tracheal intubation, laryngeal masks, bronchial intubation, visual bronchial intubation, tracheostomy tubes, anesthesia masks, artificial noses, anesthesia breathing circuits, electronic analgesia pumps, catheters, drainage bags, and various other medical instruments [2] Financial Performance - For Q1 2025, the company reported revenue of 348 million yuan, a year-on-year increase of 12.60%, and a net profit of 58.92 million yuan, up 17.25%, with a gross profit margin of 44.78% [2] Market Position - As of June 11, the company's stock closed at 12.49 yuan, up 1.13%, with a rolling price-to-earnings (PE) ratio of 16.04, marking a new low in 108 days, and a total market capitalization of 3.658 billion yuan [1] - In comparison to the medical device industry, which has an average PE of 50.99 and a median of 36.90, the company ranks 38th in terms of PE [1][3] Shareholder Information - As of March 31, 2025, the number of shareholders for the company was 17,604, an increase of 318 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]

关于募集资金使用完毕并注销募集资金专户的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 证券代码：603309 证券简称：维力医疗 公告编号：2025-039 广州维力医疗器械股份有限公司 截至本公告披露日，公司2021年非公开发行股票募集资金已按规定全部使用完毕，全部募集资金专户均 已注销完毕。 一、募集资金基本情况 经中国证券监督管理委员会《关于核准广州维力医疗器械股份有限公司非公开发行股票的批复》（证监 许可〔2021〕734号）核准，广州维力医疗器械股份有限公司（以下简称"公司"）以非公开发行股票方 式向特定投资者发行人民币普通股（A股）29,632,218股，发行价格为每股13.48元，募集资金总额为人 民币399,442,298.64元，募集资金净额为人民币392,814,940.16元。上述募集资金到位情况已经华兴会计 师事务所（特殊普通合伙）审验，并于2021年12月31日出具了《广州维力医疗器械股份有限公司验资报 告》（华兴验字[2021]21000110033号）。 截至本公告披露日，公司2021年非 ...

Core Viewpoint - Vili Medical has received certification for its urological guide wire from the Canadian Ministry of Health, which allows for legal sales in the Canadian market, potentially enhancing overseas market promotion and sales [1][4]. Group 1: Company Announcements - Vili Medical's urological guide wire has been certified as a Class II medical device by the Canadian Ministry of Health, with the certification issued on May 28, 2025 [1][4]. - The company has completed the use of funds raised from its non-public stock issuance in 2021, totaling approximately 399.44 million yuan, with all fundraising accounts now closed [2][4]. - The funds were allocated to various projects, including the construction of a marketing center, production of anti-infection catheters, and the establishment of a research and development center [2]. Group 2: Financial Information - The non-public issuance involved 29,632,218 shares at a price of 13.48 yuan per share, resulting in a net amount of approximately 392.81 million yuan after expenses [2]. - The remaining balance of 2,456.97 yuan from the research and development project has been transferred to supplement working capital, with the project expected to be operational by December 31, 2025 [2].